Status:

COMPLETED

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) pl...

Eligibility Criteria

Inclusion

  • For MAIN period (NN1250-3582):
  • Type 2 diabetes mellitus for at least 6 months
  • Ongoing daily treatment with insulin (premix, self-mix, basal only, basal bolus) for at least 3 months with/without oral anti-diabetics drug (OAD) prior to trial start
  • HbA1c 7.0-10.0 % (both inclusive)
  • Body Mass Index (BMI) below or equal to 40.0 kg/m\^2
  • For EXTENSION period (NN1250-3667):
  • Completion of the 52 week treatment period in NN1250-3582

Exclusion

  • For MAIN period (NN1250-3582):
  • Treatment with other insulin regimens than premix, self-mix, basal only, basal bolus within 3 months
  • Cardiovascular disease within the last 6 months
  • Uncontrolled treated/untreated severe hypertension
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures
  • Cancer and medical history of cancer

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 28 2010

Estimated Enrollment :

1006 Patients enrolled

Trial Details

Trial ID

NCT00972283

Start Date

September 1 2009

End Date

October 28 2010

Last Update

April 6 2017

Active Locations (136)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 34 (136 locations)

1

Novo Nordisk Investigational Site

Alexander City, Alabama, United States, 35010

2

Novo Nordisk Investigational Site

Birmingham, Alabama, United States, 35209

3

Novo Nordisk Investigational Site

Goodyear, Arizona, United States, 85395

4

Novo Nordisk Investigational Site

Peoria, Arizona, United States, 85381